Q-omics provides the consensus-scored RPS27P23 profile across patient tissues and cancer cell-line models. RPS27P23 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPS27P23 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPS27P23 RNA expression shows 6,536 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, KIRC, and STAD as cancer lineages where RPS27P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27P23 survival associations across molecular data types. RPS27P23 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27P23 RNA expression–survival associations across cancer types. High RPS27P23 expression shows unfavorable associations in KIRP, but favorable associations in CESC, LUSC, BLCA, SKCM and MESO. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RPS27P23 RNA expression.
This table summarizes RPS27P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS27P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27P23 shows lower tumor expression in KICH, LUAD and STAD and higher tumor expression in KIRC, CHOL and LIHC. The KIRC box plot shows higher RPS27P23 RNA expression in tumor versus normal tissue (log2 FC = +0.280, t-test p < 0.001).
This table shows molecular features associated with RPS27P23 in patient tissues and cancer cell lines. In patient samples, RPS27P23 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
